CIRM Funded Clinical Trials

A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants


Disease Area:
Immune Disease, Pediatrics, Severe Combined Immunodeficiency, X-linked (X-SCID)
Investigator:
Dr. Judith A Shizuru
Institution:
Stanford University
CIRM Grant:
DR2A-05365 (Closed)
Award Value:
$18,990,683.40
Investigator:
Dr. Judith A Shizuru
Institution:
Stanford University
CIRM Grant:
CLIN2-11431-A (Closed)
Award Value:
$1,113,486.70
Investigator:
Wendy Pang
Institution:
Jasper Therapeutics, Inc.
CIRM Grant:
CLIN2-11431-B (Active)
Award Value:
$2,313,398.00
Trial Sponsor:
Stanford University and Jasper Therapeutics, Inc.
Trial Stage:
Phase 1/2
Trial Status:
Recruiting
Targeted Enrollment:
40
ClinicalTrials.gov ID:
NCT02963064

Details:

This trial proposes to replace SCID patients’ dysfunctional immune cells with healthy ones using a safer form of bone marrow transplant (BMT). Current BMT procedures must use toxic chemotherapy to make space in the bone marrow for the healthy transplanted stem cells to engraft. The Stanford team will instead test a safe, non-toxic protein called a monoclonal antibody that targets and removes the defective blood forming stem cells. The hope is that this treatment will promote the engraftment of the transplanted stem cells in the patient. If successful, the procedure could open up similar BMT therapies to patients with other auto-immune diseases such as multiple sclerosis, lupus or diabetes that are generally not candidates for BMT currently. 

Design:

Open label, dose escalation trial.

Goal:

Safety. Dosing. Efficacy - hematopoietic stem cell engraftment, immune reconstitution.

Updates:

Enrolling.

News about this clinical trial:

Contact Trial Sponsor

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website

ClinicalTrials.gov